Compare Abeona Therapeutics Inc (ABEO) vs Nutrien Ltd (NTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nutrien Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Nutrien Ltd trades at $66.06 (market cap $31.34B). The key difference: Nutrien Ltd is far larger — about 83.9× Abeona Therapeutics Inc's market cap, and Nutrien Ltd pays a 3.37% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NTR | |
|---|---|---|
Market Cap | $373.32M | $31.34B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $83.94 |
52-Week Low | $4.17 | $53.64 |
Enterprise Value | $228.22M | $44.51B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Nutrien (NTR) trades at $65.32, up 0.4% with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with Q1 2026 earnings beating estimates and revenue growth projected to $27.8B in 2026. Analyst consensus is strongly bullish with a $81.86 price target, representing 25% upside potential from current levels.
NTR presents value with attractive valuation multiples (P/E 13.14, P/S 1.12) and strong fertilizer demand fundamentals. Key risks include volatile input costs, supply chain disruptions, and debt refinancing needs. The stock offers dividend income with recent $0.55 payout, positioning it as a compelling agribusiness investment amid global food security trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
